<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04962334</url>
  </required_header>
  <id_info>
    <org_study_id>rmc013521ctil</org_study_id>
    <nct_id>NCT04962334</nct_id>
  </id_info>
  <brief_title>Effect of Nutritional Formula Supplementation on Growth of Prepubertal Children Treated With Stimulants Medications for Attention Deficit Hyperactivity Disorder (ADHD)</brief_title>
  <official_title>Effect of Nutritional Formula Supplementation on Growth of Prepubertal Children Treated With Stimulants Medications for ADHD. A Randomized Double-blind, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NG Solutions Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study is a double blind, randomized, placebo controlled study. The aim of the&#xD;
      study is to evaluate the effect of nutritional formula supplementation on growth of&#xD;
      prepubertal children treated with stimulants medications of ADHD.&#xD;
&#xD;
      70 Participants treated with stimulants medications of ADHD will be randomly assigned either&#xD;
      to the intervention group or the placebo control group. Randomization for the two study&#xD;
      groups will be made in a ratio of 1:1. Both participants and study team will be blinded to&#xD;
      the type of treatment that each patient will receive during the study. Randomization will be&#xD;
      stratified according to gender.&#xD;
&#xD;
      Participants in the intervention groups will be treated with the study formula and&#xD;
      participants in the control group will be treated with a placebo low caloric formula (Powder&#xD;
      added to water). The study will continue for 6 months of intervention versus active placebo,&#xD;
      with additional 6 months (an extension period), in which participants at both groups, the&#xD;
      intervention and the placebo, will be offered to continue their participation in the study&#xD;
      with the active study supplement.&#xD;
&#xD;
      In addition, 30 prepubertal healthy siblings will be recruited to the study in order to&#xD;
      compare baseline eating and physical activity patterns of ADHD children treated with&#xD;
      stimulants to their healthy untreated siblings at the same age range. Participants' siblings&#xD;
      will only complete once the nutritional and physical activity questionnaire and report height&#xD;
      and weight measurements.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>height standard deviation score (SDS)</measure>
    <time_frame>at 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>weight standard deviation score</measure>
    <time_frame>at 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>BMI SDS</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat Mass</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lean body mass</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle mass</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in dietary patterns measured by Child Eating Behaviour Questionnaire</measure>
    <time_frame>At 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ADHD symptoms measured by Vanderblit ADHD Parent Rating Scale</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in physical activity patterns measured by physical activity questionnaire</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>height SDS</measure>
    <time_frame>at 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Weight SDS</measure>
    <time_frame>at 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>BMI SDS</measure>
    <time_frame>at 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Fat mass</measure>
    <time_frame>at 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Lean body mass</measure>
    <time_frame>at 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Muscle mass</measure>
    <time_frame>at 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in dietary patterns measured by Child Eating Behaviour Questionnaire</measure>
    <time_frame>at 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in ADHD symptoms measured by Vanderblit ADHD Parent Rating Scale</measure>
    <time_frame>at 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in physical activity measured by physical activity questionnaire</measure>
    <time_frame>at 12 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>ADHD - Attention Deficit Disorder With Hyperactivity</condition>
  <arm_group>
    <arm_group_label>Nutritional Standardized Supplementation Formula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powder added to water, containing about 25% of recommended daily recommended intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Low caloric formula (Powder added to waster) without added vitamins and minerals</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nutritional supplementation standardized formula.</intervention_name>
    <description>Powder added to water, containing about 25% of recommended daily recommended intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake</description>
    <arm_group_label>Nutritional Standardized Supplementation Formula</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Low caloric formula (powder added to water) without added vitamins and minerals</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Boys aged ≤ 10 years and girls aged ≤ 9 years.&#xD;
&#xD;
          2. Children treated with stimulants medications for ADHD for at list 3 months.&#xD;
&#xD;
          3. Prepubertal -Tanner stage 1 (gonadarche) (boys: testicular volume &lt; 4, girls: breast&#xD;
             at Tanner stage 1)&#xD;
&#xD;
          4. Normal weight status: BMI-SDS ≤ 85th percentile for age and gender according to the&#xD;
             CDC 2000 growth charts&#xD;
&#xD;
          5. Signing inform consent forms&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of GH Deficiency or treatment with GH&#xD;
&#xD;
          2. Any known chronic disease or dysmorphic syndrome including bone diseases, organic&#xD;
             brain diseases, neurological disease, past or current malignancy, chronic cardiac,&#xD;
             renal or pulmonary problems&#xD;
&#xD;
          3. Any known gastrointestinal disease including malabsorption&#xD;
&#xD;
          4. Any known organic reason for growth retardation&#xD;
&#xD;
          5. Milk allergy.&#xD;
&#xD;
          6. Any chronic treatment with additional medication beside stimulants that might affect&#xD;
             appetite, weight, or growth (for example SSRI's).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moshe Phillip, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Schneider Children's Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Moshe Phillip, Prof</last_name>
    <phone>972-3-9253282</phone>
    <email>mosheph@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alona Hamou, Msc</last_name>
    <phone>972-3-9253747</phone>
    <email>alonah@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Schneider children's medical center</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Moshe Phillip, Prof</last_name>
      <phone>972-39253282</phone>
      <email>mosheph@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Naama Fish, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liora Lazar, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 29, 2021</study_first_submitted>
  <study_first_submitted_qc>July 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2021</study_first_posted>
  <last_update_submitted>July 4, 2021</last_update_submitted>
  <last_update_submitted_qc>July 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

